Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Millions of Medicaid beneficiaries have limited access to Type 2 diabetes medications that reduce the risk of cardiovascular disease, according to a study published April 22 in Annals of Internal ...

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most ...